INZY

Inozyme Pharma Inc

NASDAQ

Add Alert

INZY

Inozyme Pharma Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

AJ Freely

08/04/23 8:22 AM

Post #16

$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment

Monksdream PremiumMember

07/23/23 6:23 AM

Post #15

INZY new 52 week high

INFINITI

02/17/23 8:19 AM

Post #14

Jess070283 Free

02/16/23 10:10 AM

Post #13

Have a feeling this about to squeeze into a halt soon…..

tj9938

01/06/23 11:00 AM

Post #12

Great week so far. Gotta keep it movin.

tj9938

12/30/22 1:58 PM

Post #11

Quietest board out there

ErnieBilco PremiumMember

04/26/22 11:00 AM

Post #10

Grabbed a starter here today

crudeoil24 PremiumMember

04/18/22 9:41 PM

Post #9

INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com

crudeoil24 PremiumMember

04/18/22 9:36 PM

Post #8

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

crudeoil24 PremiumMember

04/18/22 9:33 PM

Post #7

Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY

tw0122

04/14/22 8:31 AM

Post #5

Re: #4: @crudeoil24 - The offering is expected to close on or

I like the BioXc chart looks better. Thanks for all the good insight.

crudeoil24 PremiumMember

04/14/22 8:24 AM

Post #4

Re: #3: @tw0122 - This analyst know about the offering? Inozyme Pharma,

The offering is expected to close on or about April 19, 2022

tw0122

04/14/22 8:21 AM

Post #3

Re: #1: @crudeoil24 - H.C. Wainwright analyst Edward White maintained a Buy

This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.

crudeoil24 PremiumMember

04/14/22 8:16 AM

Post #2

Re: #1: @crudeoil24 - H.C. Wainwright analyst Edward White maintained a Buy

PT > 33.00

crudeoil24 PremiumMember

04/14/22 8:16 AM

Post #1

H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.